Guardant Health Reports Strong Preliminary Q4 and Full Year 2025 Results with Accelerating Revenue and Shield Growth

summarizeSummary

Guardant Health announced robust preliminary unaudited financial results for Q4 and full year 2025, showcasing accelerated revenue growth and significant increases in both oncology and Shield screening test volumes.

check_boxKey Events

• Accelerated Revenue Growth

  Reported preliminary full year 2025 revenue of approximately $981 million, a 33% increase year-over-year, with Q4 revenue up 39% to $280 million.

• Significant Shield Test Volume Increase

  Shield screening tests surged to approximately 38,000 in Q4 2025, a substantial increase from 6,400 in the prior year period, with nearly 100,000 patients screened since FDA approval.

• Strong Oncology Test Volume

  Oncology test volumes grew 38% in Q4 2025 to approximately 79,000 tests, contributing to a 34% increase for the full year.

• Healthy Cash Position

  The company maintained a strong liquidity position with approximately $1.3 billion in cash, cash equivalents, restricted cash, and marketable debt securities as of December 31, 2025.

auto_awesomeAnalysis

Guardant Health's preliminary Q4 and full year 2025 results indicate strong operational performance, with revenue growth accelerating to 33% for the full year. The substantial increase in Shield screening tests, from 6,400 to 38,000 in Q4, highlights successful market penetration and adoption of its colorectal cancer screening product. This strong growth, coupled with a healthy cash balance of $1.3 billion, provides a positive outlook for the company's continued expansion in precision oncology and screening, especially as it trades near its 52-week high.